Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Intellia Therapeutics to Present at October Healthcare Investor Conferences
-
Arrowhead to Present at Chardan Gene Therapy Conference
-
Smith Micro Software (SMSI) Reports $5.5M Private Placement of Newly Designated Convertible Preferred Stock
-
Smith Micro Announces $5.5 Million Private Placement of Newly Designated Convertible Preferred Stock
-
Genius Brands Int'l (GNUS) Announces $6.4M Registered Direct Offering of Common Stock
-
Genius Brands International Announces $6.4 Million Registered Direct Offering
-
Voyager Therapeutics to Present at Investor Conferences in October
-
Editas Medicine to Participate in Investor Conferences in October
-
Spark Therapeutics to Participate in Multiple Conferences in October
-
REGENXBIO to Present at Upcoming Investor Conferences
-
miRagen Therapeutics to Present at the Chardan Inaugural Gene Therapy Conference
-
FBR Capital Markets & Co. Expands Team with Four New Healthcare Analysts and Experienced Investment Banker
-
Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Chardan Capital Markets Upgrades Sunworks (SUNW) to Buy
-
AGTC to Present at Upcoming Gene Therapy Conferences
-
Nightstar Therapeutics plc (NITE) IPO Opens Up 23%
-
Adverum Biotechnologies to Present at Upcoming Conferences
-
VBL Therapeutics to Present at the Chardan Gene Therapy Conference
-
Nightstar Therapeutics PLC (NITE) Prices 5.36M ADS IPO at $14/Sh
-
Nightstar Announces Pricing of Initial Public Offering
-
UPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital Markets
-
Iovance Biotherapeutics, Inc. Announces Closing of $57.5 Million Common Stock Public Offering
-
Axovant Sciences (AXON) Job Posting Could Suggest NDA Filing - Chardan Capital Markets
-
Iovance Biotherapeutics (IOVA) Prices 7.692M Share Common Offering at $6.50/Sh
-
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock
-
Alnylam (ALNY) Data a 'Clear Positive' for The Medicines Company (MDCO) Inclisiran - Chardan
-
Audentes Therapeutics to Present at Upcoming Investor Conferences
-
Astrotech Reports Fiscal Year 2017 Financial Results
-
Amicus Therapeutics (FOLD) PT Lowered to $16.50 at Chardan Capital Markets, Keeps 'Buy'
-
Axovant Sciences (AXON): Reiterating Sell - Chardan
-
HealthEquity to Present at Conferences in September
-
Atlantic Acquisition Corp. Announces that Common Stock and Rights to Commence Separate Trading on or about September 7, 2017
-
Regenxbio Inc. (RGNX) PT Raised to $75 at Chardan Capital Markets
-
Iovanace Biotherapeutics (IOVA): Fast Track Status Validates Regulatory Path - Chardan
-
Nightstar Files Registration Statement For Proposed Initial Public Offering
-
Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Pre-Open Movers 08/29: (MOV) (CTLT) (IMGN) Higher; (FINL) (ACOR) (JILL) Lower (more...)
-
Chardan Capital Markets Downgrades Intellia Therapeutics (NTLA) to Neutral
-
Chardan Capital Markets Starts Tivity Health (TVTY) at Neutral
-
I-AM Capital Acquisition Company Completes $50 Million Initial Public Offering
-
I-AM Capital Acquisition Company Announces Pricing of $50,000,000 Initial Public Offering
-
miRagen Therapeutics (MGEN) PT Raised to $29 at Chardan Capital Markets
-
Chardan Capital Markets Starts Foresight Autonomous ADS (FRSX) at Buy
-
AveXis (AVXS): 3 Catalysts, Raising PT To $135 - Chardan
-
Akari Therapeutcis (AKTX): Skeptical Of Coversin In PNH - Chardan
-
Amicus Therapeutics (FOLD): Raising PT to $17.50 - Chardan
-
Alnylam Pharma (ALNY): Cutting PT to $124 - Chardan
-
Editas Medicine Announces Second Quarter 2017 Results and Update
-
Atlantic Acquisition Corp. Announces Pricing of $40,000,000 Initial Public Offering
-
Vuzix Corp. (VUZI) Announces $8.63M Common Stock Offering

